European Heart Journal Advance Access originally published online on February 13, 2007
European Heart Journal 2007 28(13):1592-1597; doi:10.1093/eurheartj/ehl505
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony
1 Division of Cardiology, Department of Internal Medicine, Medical University Graz, Auenbruggerplatz 15, 8036 Graz, Austria
2 Department of Internal Medicine II, Medical University Vienna, Vienna, Austria
3 Good Hope Hospital, Sutton Coldfield, UK
4 University of Birmingham, Edgbaston, Birmingham, UK
5 Department of Internal Medicine III, University of Cologne, Cologne, Germany
6 Nouveles Cliniques Nantaises, Nantes, France
7 Division of Cardiology, University Hospital Lausanne, Lausanne, Switzerland
8 IRCCS Policlinico San Matteo, Pavia, Italy
9 Centre Cardio-Pneumologique, University Hospital Rennes, Rennes, France
10 Department of Cardiology, University of Hull, Kingston upon Hull, UK
Received 26 January 2006; revised 12 May 2006; accepted 11 January 2007; online publish-ahead-of-print 13 February 2007.
* Corresponding author. Tel: +49 43 316 385 2544; fax: +49 43 316 385 3733. E-mail address: friedrich.fruhwald{at}meduni-graz.at
See page 1541 for the editorial comment on this article (doi:10.1093/eurheartj/ehm169)
Aims: The Cardiac Resynchronization-Heart Failure (CARE-HF) study demonstrated that cardiac resynchronization therapy (CRT) could reduce morbidity and mortality and improve cardiac function in patients with moderate or severe heart failure secondary to left ventricular systolic dysfunction and markers of cardiac dyssynchrony. The purpose of this analysis was to investigate the effect of CRT on plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-pro-BNP), a powerful marker of cardiac dysfunction and prognosis.
Methods and results: Blood samples were collected routinely at baseline and 3 and 18 months. Plasma was separated by cool centrifugation and stored at –70°C until transported to a central laboratory for analysis of NT-pro-BNP using a standard commercial assay. Cardiac function was assessed echocardiographically. At baseline, median plasma concentration of NT-pro-BNP was similar in patients assigned to CRT or medical therapy [1920 pg/mL (inter-quartile range (IQR) 744–4288) and 1809 pg/mL (IQR 719–3949), respectively]. The differences in medians between the CRT and medical therapy groups were highly significant at both 3 months (537 pg/mL; P < 0.0001) and 18 months of follow-up (567 pg/mL; P < 0.0001). These differences could not be accounted for by changes in pharmacological therapy or renal function but were associated with improvement in ventricular volumes and function.
Conclusion: CRT exerts an early and sustained reduction in NT-pro-BNP. This appears to reflect improvements in ventricular function. NT-pro-BNP may be a simple method for monitoring the effects of CRT.
Key Words: Heart failure • Cardiac resynchronization therapy • Neurohormones • NT-pro-BNP
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- It's the metabolism, stupid! Why electrophysiologists should be interested in biomarkers of heart failure
- Christoph Stellbrink
EHJ 2007 28: 1541-1542.[Extract] [Full Text]
This article has been cited by other articles:
|
|
 |
|
  J. Cleland, N. Freemantle, S. Ghio, F. Fruhwald, A. Shankar, M. Marijanowski, Y. Verboven, and L. Tavazzi Predicting the Long-Term Effects of Cardiac Resynchronization Therapy on Mortality From Baseline Variables and the Early Response: A Report From the CARE-HF (Cardiac Resynchronization in Heart Failure) Trial J. Am. Coll. Cardiol., August 5, 2008; 52(6): 438 - 445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kypta, C. Steinwender, J. Kammler, F. Leisch, and R. Hofmann Long-term outcomes in patients with atrioventricular block undergoing septal ventricular lead implantation compared with standard apical pacing Europace, May 1, 2008; 10(5): 574 - 579. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Daniels and A. S. Maisel Natriuretic Peptides J. Am. Coll. Cardiol., December 18, 2007; 50(25): 2357 - 2368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Maisel Biomarkers in Heart Failure: Does Prognostic Utility Translate to Clinical Futility? J. Am. Coll. Cardiol., September 11, 2007; 50(11): 1061 - 1063. [Full Text] [PDF]
|
|